Company Overview and News

 
Govt may infuse Rs 2,350cr in Central Bank to boost capital base

2018-09-20 moneycontrol
In a bid to help the Central Bank of India meet capital requirements as per the Reserve Bank of India (RBI)'s guidelines, the government is planning to infuse Rs 2,350 crore in the bank, according to a report by Business Standard.
IOB ALBK 532418 532401 VIJAYABANK 532179 532388 PNJZY 532121 532461 CRPKY 532480 PNB CORPBANK DENABANK ANDHRABANK

 
Dena Bank, Bajaj Corp, UCO Bank, MMTC, Jubilant Food top gainers among BSE Group A stocks

2018-09-18 moneycontrol
The Indian benchmark indices continues to trade in the red and have extended the earlier loses this Tuesday afternoon with the Nifty50 down 73 points and is trading at 11,304 while the Sensex is trading lower by 214 points at 37,370.
500429 GALLANTT 532726 532505 HINDUNILVR 533155 JUBLFOOD 532179 532121 CRPKY UNIPHOS JBLWY 500696 CORPBANK UCOBANK DENABANK

 
Corporation Bank - Updates

2018-09-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532179 CRPKY CORPBANK

 
Independent director of Jaypee Infratech ‘Sham Lal Mohan’ resigns

2018-09-17 freepressjournal.in
New Delhi: Jaypee Infratech, which is facing insolvency proceedings, Monday said that the company’s independent director Sham Lal Mohan has resigned citing personal reasons. Last week, three independent directors Lalit Bhasin, Keshav Prasad Rau and Basant Kumar Goswami had resigned from the board.
UBNC AXB JIPKY IBN JPASSOCIAT 532525 532215 MAHABANK 532532 AXBKY 532179 SYNDIBANK AXBA ICICIBANK 533207 532276 JPINFRATEC CRPKY AXISBANK 532174 CORPBANK

 
Another independent director of Jaypee Infratech resigns; fourth in last one week

2018-09-17 moneycontrol
Jaypee Infratech, which is facing insolvency proceedings, Monday said that the company's independent director Sham Lal Mohan has resigned citing personal reasons. Last week, three independent directors Lalit Bhasin, Keshav Prasad Rau and Basant Kumar Goswami had resigned from the board.
UBNC AXB JIPKY IBN JPASSOCIAT 532525 532215 MAHABANK 532532 AXBKY 532179 SYNDIBANK AXBA ICICIBANK 533207 532276 JPINFRATEC CRPKY AXISBANK 532174 CORPBANK

 
Corporation Bank - Updates

2018-09-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532179 CRPKY CORPBANK

 
One more independent director of Jaypee Infratech resigns

2018-09-12 moneycontrol
Debt-ridden Jaypee Infratech, which is facing insolvency proceedings,said that its independent director Lalit Bhasin has resigned from the board.
UBNC AXB JIPKY IBN JPASSOCIAT 532525 532215 MAHABANK 532532 AXBKY 532179 SYNDIBANK AXBA ICICIBANK 533207 532276 JPINFRATEC CRPKY AXISBANK 532174 CORPBANK

 
ICICI Banks files insolvency plea against Jaiprakash Associates

2018-09-10 livemint
New Delhi: Leading private sector lender ICICI Bank has filed insolvency petition against Jaiprakash Associates before the National Company Law Tribunal (NCLT).
JIPKY 532538 532215 MAHABANK SYNDIBANK 533207 AXISBANK UCLQY UBNC AXB IBN JPASSOCIAT UCLQF 532525 ULTRACEMCO AXBKY 532532 532179 AXBA ICICIBANK 532276 CRPKY JPINFRATEC 532174 CORPBANK

 
Jaypee Infratech’s two independent directors resign

2018-09-10 livemint
New Delhi: Jaypee Infratech Ltd, which is facing insolvency proceedings, Monday said that the company’s two independent directors—Keshav Prasad Rau and Basant Kumar Goswami —have resigned.
UBNC AXB JIPKY IBN JPASSOCIAT 532525 532215 MAHABANK 532532 AXBKY 532179 SYNDIBANK AXBA ICICIBANK 533207 532276 JPINFRATEC CRPKY AXISBANK 532174 CORPBANK

 
Corporation Bank plea in NCLT against Essar Ports arm

2018-09-07 livemint
Mumbai: Corporation Bank has approached the Ahmedabad bench of the National Company Law Tribunal (NCLT) against Essar Bulk Terminal Salaya Ltd, a subsidiary of Essar Ports, for allegedly defaulting on loans totalling more than ₹196 crore.
532179 ICICIBANK CRPKY 532174 IBN CORPBANK

 
Corporation Bank - Shareholders meeting

2018-09-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532179 CRPKY CORPBANK

 
Corporation Bank - Shareholders meeting

2018-09-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532179 CRPKY CORPBANK

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...